A 28.8-day half-life is not a footnote in a Phase IIa readout — it is the architectural decision that determines whether RESP-X becomes a quarterly infusion patients can realistically maintain or another antibacterial program that collapses on adherence. Infex Therapeutics‘ data from its randomized, double-blinded, placebo-controlled study in non-cystic fibrosis bronchiectasis patients colonized with Pseudomonas aeruginosa show that the 10 mg/kg dose sustains serum coverage over the PK/PD target long enough to support three-monthly dosing intervals, and that exposure in lung epithelial lining fluid was confirmed by bronchoscopy at 48 hours post-dose across all treated patients. That lung deposition confirmation matters enormously: systemic antibody programs targeting pulmonary pathogens routinely fail here, and Infex has now shown the drug actually gets to the tissue where Pa is causing damage.
The mechanism distinguishes this program from every antibiotic in the bronchiectasis pipeline. RESP-X targets PcrV, the cap protein of Pa’s Type III Secretion System, neutralizing the pathogen’s primary tool for injecting exotoxins into host cells and evading phagocytosis. It does not kill bacteria. That distinction is clinically significant in chronic colonization: a bactericidal approach selects for resistance over the years-long treatment course these patients require, whereas an anti-virulence strategy disarms without eliminating, preserving the patient’s immune system to do the clearing. Every Pa isolate collected from sputum throughout the study encoded PcrV and bound RESP-X — 100% target coverage is the kind of result that removes a major Phase III failure mode from the risk ledger.
The efficacy signal is preliminary but pointed in the right direction. Pa-positive patients experienced fewer exacerbations from day 1 through day 180 compared with their own prior 12-month history, with a p-value of 0.08. In a Phase IIa study not powered for efficacy, that signal combined with complete target engagement and clean immunogenicity data — zero anti-drug antibodies detected at any timepoint — constitutes a credible biological rationale to advance. No infusion reactions, no dose-responsive adverse events, no withdrawals. The safety profile removes another common Phase II attrition driver.
The single variable that will define this program’s trajectory is the exacerbation rate in the upcoming Phase IIb/III efficacy study’s placebo arm. NCFB trial history is littered with failures driven by lower-than-expected placebo exacerbation frequency, which collapses statistical power regardless of drug effect. Infex’s ability to enrich for high-exacerbation-frequency Pa-colonized patients at enrollment will determine whether the 0.08 signal becomes a registration-enabling result.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
